Recurrent Chylous Pleural Effusions in a Patient Treated With Dasatinib

Dasatinib is a second-generation BCR-ABL tyrosine kinase inhibitor (TKI) that is approved for the treatment of chronic myeloid leukemia (CML), a myeloproliferative disorder seen commonly in adults over the age of 50. Dasatinib is superior in tolerance and efficacy to first-generation TKIs such as im...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasir, Syed Alishan, Calavia Liano, Hugo, Manfredi, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450929/
https://www.ncbi.nlm.nih.gov/pubmed/36106302
http://dx.doi.org/10.7759/cureus.27778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450929/
https://www.ncbi.nlm.nih.gov/pubmed/36106302
http://dx.doi.org/10.7759/cureus.27778

Ejemplares similares